Renata Ponsirenas

Renata Ponsirenas

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
JBJonathan S. Bromberg
Jonathan S. Bromberg
DBDaniel Brennan
Daniel Brennan
DTDavid J. Taber
David J. Taber
MCMatthew Cooper
Matthew Cooper
SASanjiv Anand
Sanjiv Anand
MWMatthew R. Weir
Matthew R. Weir
Donor-derived cell-free DNA (dd-cfDNA) is a biomarker that enables the early detection of immune-mediated graft injury. This study evaluated the clinical utility of dd-cfDNA in predicting the presence of biopsy-proven rejection (BPAR). We analyzed 1,070 biopsies from 1,743 kidney transplant recipients enrolled in the prospective, multicenter Kidney Allograft Outcomes AlloSure Registry (KOAR). Biopsies were grouped into surveillance or for-cause groups and stratified by dd-cfDNA status: elevated, non-elevated, or not tested. Rejection yield was significantly higher when dd-cfDNA was elevated: 39% vs. 7% in the surveillance group and 47% vs. 12% in the for-cause group (p<0.0001). Biopsies with elevated dd-cfDNA and rejection diagnoses more frequently demonstrated ABMR and mixed rejection, whereas biopsies performed with non-elevated dd-cfDNA most often showed no rejection, borderline, or TCMR 1A. The AUROC for BPAR detection was 0.789. These findings demonstrate dd-cfDNA levels can improve the pre-test probability of BPAR in both surveillance and for-cause settings. Therefore, dd-cfDNA can optimize biopsy utilization by identifying renal transplant patients who are most likely to have histological rejection.

26 November 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DLDuncan Lewis
Duncan Lewis
RPRenata Ponsirenas
Renata Ponsirenas
NGNatali Gulbahce
Natali Gulbahce
LHLeah J. Hooey
Leah J. Hooey
JCJoanna M. Chaffin
Joanna M. Chaffin
AZAli Zarrinpar
Ali Zarrinpar
The diagnosis of graft-versus-host-disease (GVHD) after solid organ transplantation is made difficult by its variable clinical presentation and lack of sensitive and specific biomarkers to evaluate the immune state of transplant recipients. Emerging noninvasive diagnostic techniques like the quantification of donor-derived cell-free DNA (dd-cfDNA) for surveillance may improve the current standard-of-care. Herein, we report the use of this methodology in a patient with GVHD and corresponding levels of dd-cfDNA without any evidence of graft injury. Correlation of dd-cfDNA levels with the clinical course and its novel application here could lead to improvements in the rapid diagnosis of GVHD and in monitoring of response to treatment.

13 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JMJoao Manzi
Joao Manzi
CHCamilla Oliveira Hoff
Camilla Oliveira Hoff
RFRaphaella De Paula Ferreira
Raphaella De Paula Ferreira
RPRenata Ponsirenas
Renata Ponsirenas
GSGennaro Selvaggi
Gennaro Selvaggi
PAPhillipe Abreu
Phillipe Abreu
The liver is the world’s sixth most common primary tumor site, responsible for approximately 5% of all cancers and over 8% of cancer-related deaths. Hepatocellular carcinoma (HCC) is the predominant type of liver cancer, accounting for approximately 75% of all primary liver tumors. A major therapeutic tool for this disease is liver transplantation. Two of the most significant issues in treating HCC are tumor recurrence and graft rejection. Currently, the detection and monitoring of HCC recurrence and graft rejection mainly consist of imaging methods, tissue biopsies, and alpha-fetoprotein (AFP) follow-up. However, they have limited accuracy and precision. One of the many possible components of cfDNA is circulating tumor DNA (ctDNA), which is cfDNA derived from tumor cells. Another important component in transplantation is donor-derived cfDNA (dd-cfDNA), derived from donor tissue. All the components of cfDNA can be analyzed in blood samples as liquid biopsies. These can play a role in determining prognosis, tumor recurrence, and graft rejection, assisting in an overall manner in clinical decision-making in the treatment of HCC.

1 August 2018 in Transplant Immunology
Verified
Journal Article
Closed access
HCHelena B. Cazarote
Helena B. Cazarote
SSSilvia Emiko Shimakura
Silvia Emiko Shimakura
JVJoana S. Valdameri
Joana S. Valdameri
FCFabiana L.C. Contieri
Fabiana L.C. Contieri
CGCristina Q.C. von Glehn
Cristina Q.C. von Glehn
RPRenata Ponsirenas
Renata Ponsirenas

1 September 2018 in Transplantation Direct
Verified
Journal Article
Open access
RPRenata Ponsirenas
Renata Ponsirenas
HCHelena B. Msc Cazarote
Helena B. Msc Cazarote
SAStanley de Almeida Md Araújo
Stanley de Almeida Md Araújo
DWDavid Campos Md Wanderley
David Campos Md Wanderley
SSSilvia Shimakura
Silvia Shimakura
VSVanessa Santos Sotomaior
Vanessa Santos Sotomaior
Background The identification of low-level antibodies by single-antigen bead methodology has brought advancements to risk evaluation of kidney transplant recipients. However, the use of mean fluorescence intensity (MFI) to quantify antibodies and to guide therapy is not enough. Notably, immunoglobulin G (IgG) subclass switching is hypothesized to follow a programmed sequence after an emergency signal from the germinal center. In transplantation this process is not clear yet. In the present study, we sequentially evaluate anti-HLA donor specific antibody (DSA) subclasses, their profile changes, and C1q-binding ability and the influence of those characteristics on antibody mediated rejection (AMR) occurrence and allograft function. Methods A total of 30 DSA-positive patients were tested for IgG subclass content and C1q-binding in sequential serum samples. Results Twenty-one patients were DSA-positive before transplant; patients sensitized only by transfusion or pregnancies had IgG1 and/or IgG3, and patients sensitized by both transfusion and pregnancies or previous transplant showed a broader range of IgG subclasses. C1q binding was detected in high MFI made up of IgG1 or multiple IgG subclasses. Only 4 patients were positive for C1q posttransplantation and 3 of these showed an increase in MFI, changes in subclasses patterns, AMR, and allograft dysfunction. Conclusions Posttransplant evaluation of DSA subclasses and the ability to bind C1q may be informative for both AMR occurrence and allograft dysfunction. Monitoring these events may help to better define risk and interventional time points.

14 April 2025 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
JCJayanthi Chandar
Jayanthi Chandar
VSVaka Sigurjonsdottir
Vaka Sigurjonsdottir
MDMarissa J. Defreitas
Marissa J. Defreitas
TGTara Gavcovich
Tara Gavcovich
MZMingming Zhou
Mingming Zhou
GBGeorge William Burke
George William Burke
Background: We describe our single-center experience in performing donor-derived cell-free DNA (dd-cfDNA) testing for a clinical indication in pediatric kidney transplant recipients. Methods: Dd-cfDNA was done for increase in creatinine, appearance of de novo anti-HLA antibodies (dnHLAab) and for a clinical indication. We compared clinical characteristics of patients with dd-cfDNA > 1 with those with dd-cfDNA ≤ 1 and also compared dd-cfDNA in patients with no biopsy proven rejection (BPAR) or dnHLAab with those with BPAR, and those with dnHLAab and no BPAR. Results: Chart review was performed in 106 patients with a mean age of 11.0 ± 5.5 years. When compared with 62 patients with dd-cfDNA ≤ 1, 59.0% (26/44) of patients with dd-cfDNA > 1 had BPAR (OR 13.5: 95%CI 4.6,38; p < 0.0001), and 88.1% (37/44) had dnHLAab (OR 60.3 95%CI 17.2,192.2; p < 0.0001). Patients with DQ and DR dnHLAab (OR 115.2: 95%CI 24.8, 509.5; p < 0.0001) and those with donor-specific antibodies (DSAs) (OR 50.8: 95%CI 13.0, 168.7; p < 0.0001) were likely to have dd-cfDNA > 1. A repeated measures linear mixed effect model revealed a significant difference in dd-cfDNA between those with no antibodies or BPAR (p < 0.0001) and patients with BPAR and dnHLAab, with or without DSA. At the end of the follow-up period, eGFR was 72 mL/min/1.73 m2 in those without BPAR or dnHLAab and was significantly different from those with BPAR (eGFR 51 mL/min/1.73 m2 (p < 0.0001). Conclusions: Elevated dd-cfDNA is strongly associated with BPAR, class II dnHLAab and DSAs. Conversely, low values are observed in immunoquiescent states. Dd-cfDNA can be a useful tool for non-invasive clinical decision-making. Graphical